Stroke Trials Registry

Nalmefene
Cervene® ReVex®

Action
Opioid antagonist with relative selectivity for kappa opiate receptors

Status
US FDA approved 1995 (as ReVex) for reversal of narcotic effects or overdose. Mulitcenter acute stroke trial of 291 patients showed difference between placebo and 3 dose groups in favorable outcome overall, but possible effect for patients <70. Phase III multicenter trial completed 1998, published 6/2000, showed no significant treatment effect at 6 months.

Trial(s)
= Ongoing
= Completed

Cervene Phase 2 Phase II Trial of Cervene in Acute Stroke

Cervene Phase 3 Cervene Stroke Study

Web Links and Publications

IVAX Web Site.

Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study Investigators.
Stroke 2000 Jun;31(6):1234-9.

Nalmefene. JF 1, nalmetrene, NIH 10365, ORF 11676, Arthrene, Cervene, Incystene, Revex.
Drugs R D. 1999 Jan;1(1):32-3.

UID: 31